Published in final edited form as:

J Neurovirol. 2007 December ; 13(6): 561–568. doi:10.1080/13550280701620747.

Associations of cigarette smoking with viral immune and cognitive function in human immunodeficiency virus–seropositive women

Valerie Wojna^{1,2}, Lizbeth Robles¹, Richard L Skolasky³, Raul Mayo^{1,4}, Ola Selnes⁵, Tania de la Torre¹, Elizabeth Maldonado¹, Avindra Nath⁵, Loyda M. Meléndez^{1,6}, and Jose Lasalde-Dominicci^{1,7}

¹Department of NeuroAIDS Program, University of Puerto Rico, San Juan, Puerto Rico

²Department of Internal Medicine, Neurology Section, University of Puerto Rico, San Juan, Puerto Rico

³Department of Orthopedic Surgery, Johns Hopkins University, Baltimore, Maryland, USA

⁴Department of Physical Medicine and Rehabilitation, University of Puerto Rico, San Juan, Puerto Rico

⁵Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA

⁶Department of Microbiology, University of Puerto Rico, San Juan, Puerto Rico

⁷Department of Biology and Chemistry, University of Puerto Rico, San Juan, Puerto Rico

Abstract

Cigarette smoking alters the immune system and may improve cognitive deficits in neuropsychiatric disorders. Smoking prevalence is high in human immunodeficiency virus (HIV)–infected patients; however, its effect on HIV-associated cognitive impairment remains unknown in the era of antiretroviral treatment. The authors examined associations of smoking with viral immune profile and cognitive function in a cohort of HIV-seropositive women. This observational cross-sectional study included 56 women (36 HIV-seropositive and 20 HIV-seronegative) surveyed with a tobacco questionnaire: the Fagerström Test for Nicotine Dependency. Viral immune status was obtained 6 to 12 months before questioned. Neurocognitive testing (NP) assessed verbal memory, frontal/executive function, psychomotor speed, and motor speed. A reference group of HIV-seronegative women was used to calculate standardized z-scores. Cognitive impairment was classified using a modified American Academy of Neurology criteria, adding an asymptomatic group based on NP tests. Statistics included parametric and nonparametric tests. HIV-seropositive

Address correspondence to Valerie Wojna, MD, NeuroAIDS Program, PO Box 365067, San Juan, Puerto Rico 00936-5067. vwojna@rcm.upr.edu.

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

Publisher's Disclaimer: The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

women were more likely to report a history of smoking ($P = 0.028$). Among them, current smoking correlated with higher plasma viral load ($P = 0.048$), and history of smoking correlated with lower CD4 cell count ($P = 0.027$). The authors observed no associations between cognitive impairment and either current or past history of smoking and no differences in neurocognitive domain scores between HIV-seropositive and -seronegative women or between those with and without a history of smoking. However, restricting analysis to HIV-seropositives showed a significant better performance on the frontal/executive domain in those with history of smoking. In summary, history of smoking correlated with better frontal/executive cognitive domain performance in HIV-seropositive women and with worse viral immune profile.

Keywords

cigarette smoking; cognitive impairment; HIV; nicotine; viral immune profile; women

Introduction

Cigarette smoking effect on the immune system function may depend on the smoker's duration of smoking, gender, and ethnicity (Tollerud *et al*, 1989; Tollerud *et al*, 1991; Sopori, 2002). In light and moderate smokers, the CD4 cell count increases; however, in heavy smokers, the count decreases (Holt, 1987). Nicotine, as one of the components of cigarette smoking, may be responsible for these immunological changes (Sopori, 2002). Furthermore, in the brain, nicotine may have anti-inflammatory effects (Shytle *et al*, 2004; De Simone *et al*, 2005).

Human immunodeficiency virus (HIV)–seropositive patients (Burns *et al*, 1991; Mamary *et al*, 2002; Gritz *et al*, 2004), as well as schizophrenic patients (O'Farrell *et al*, 1983; Masterson and O'Shea, 1984; Hughes *et al*, 1986; Ziedonis *et al*, 1994; de Leon *et al*, 1995), have a higher prevalence of smoking. Most previous studies involving smoking in HIV-seropositive patients were performed in men without highly active antiretroviral treatment (HAART). In the pre-HAART era, men who smoked were more likely to seroconvert to HIV than were exposed men who did not smoke. Once infected, HIV-seropositive smokers presented a higher serum β 2-microglobulin level and an increased CD4 cell count, which lasted approximately 2 years (Royce and Winkelstein, 1990; Burns *et al*, 1991). Studies performed in the post-HAART era, during which the incidence of opportunistic infections has decreased markedly, have found that smoking is associated with a decreased quality of life and an increased mortality (Page-Shafer *et al*, 1996; Turner *et al*, 2001; Crothers *et al*, 2005). Regardless of treatment modalities, no association between smoking and progression to acquired immunodeficiency syndrome (AIDS) was found (Burns *et al*, 1991; Conley *et al*, 1996; Furber *et al*, 2007).

Clinical studies on the effect of smoking on cognitive function have shown mixed or inconclusive results. Cross-sectional, longitudinal, and population-based studies involving healthy elderly subjects demonstrated that smoking is associated with poor performance in cognitively demanding tasks (Hill *et al*, 2003) and executive function (Razani *et al*, 2004) and with greater decline in the Mini-Mental Status Examination (Ott *et al*, 2004). Likewise,

smoking presents a higher risk of late-life cognitive impairment (Galanis *et al*, 1997; Richards *et al*, 2003). Nonetheless, clinical studies involving nicotine administration in healthy smokers and nonsmokers have shown an enhancement of cognitive function, mostly involving attention and psychomotor speed domains (Sacco *et al*, 2004). The prevalence of smoking is higher in subjects with neuropsychiatric disorders, such as attention deficit hyperactivity disorder, affective disorders, schizophrenia, Parkinson's disease, and Alzheimer's disease. It is likely that smoking or nicotine may improve the neurocognitive deficits present in these disorders (Sacco *et al*, 2004, 2005; Olincy *et al*, 2006). Stimulation of central nicotinic receptors has been shown to enhance neurotransmitter release, modify circuit excitability, and influence synaptic plasticity (Dani and Bertrand, 2007).

There are limited clinical studies evaluating the effect of smoking on cognitive function in people with HIV infection. Prior to HAART, Burns *et al* found that current smokers were more likely to develop AIDS dementia complex (HIV-associated dementia) than those who never smoked. However, these patients were associated with intravenous drug abuse, lower CD4 cell counts, and decreased use of antiretroviral treatment (Burns *et al*, 1991). Animal studies performed by Gonzalez-Lira *et al*, using event-related potentials (indicators of cognitive processing), observed that HIV gp120 (glycoprotein derived from HIV) interfered with cholinergic neurotransmission and affected event-related potential and motor coordination, whereas the simultaneous nicotine administration obliterated this effect (Gonzalez-Lira *et al*, 2006). In an *in vitro* model for HIV dementia consisting of cultured microglial cells synergistically activated by the addition of interferon gamma (INF γ) and HIV gp120, pretreatment with nicotine and galantamine (nicotine agonist) attenuated microglial inflammatory response to gp120 and tat (Giunta *et al*, 2004).

At present, the effect of smoking on the course of HIV-associated cognitive impairment in the HAART era remains unknown. Studies performed in the pre-HAART era involved mostly men. However, women constitute the fastest growing group of persons with HIV/AIDS, and as a group, they remain far less studied, particularly those from minority populations. Studies addressing gender differences in the clinical presentation of HIV infection have shown greater disease progression in women despite HAART (Poundstone *et al*, 2001). In addition, recent studies from our group suggest that Hispanic women may be at greater risk of HIV-associated cognitive impairment (Wojna *et al*, 2006). In this study, we examined associations of smoking history and dependence with viral immune profile and cognitive function in a cohort of HIV-seropositive women.

Results

The 36 HIV-seropositive women tended to be older on average than the 20 HIV-seronegative women (39.8 years [SD = 6.3] versus 35.9 [6.2], $P = .030$), but there were no significant differences regarding years of education (12 years), or annual income (mode of <\$5000) (Table 1). Of the 36 HIV-seropositive women, 27 presented with menstrual cycles (2 with irregular cycles, 1 with amenorrhea, and 24 with regular menses), 6 had hysterectomy, and 3 had menopause. Two women were using hormonal replacement therapy (Provera) at the time of the evaluation. All HIV-seronegative women ($n = 20$) presented with regular menstrual cycles. History of smoking was reported in 31 (55%) women. HIV-seropositive women were

more likely than seronegatives to report a history of smoking (24 of 36 versus 7 of 20, Fisher's exact $P = .028$). Among those with a history of smoking, HIV-seropositive women tended to begin smoking at a younger age (15.3 years [SD = 2.3] versus 18.1 [2.0], $P = .007$). History of smoking in the HIV-seropositive women correlated with lower CD4 cell count ($P = .027$), whereas current smoking correlated with higher plasma viral load RNA ($P = .048$). No correlations were observed between CSF viral load among HIV-seropositive women who had history or were currently smoking (Table 2). From the 15 HIV-seropositive women who reported to be current smokers, 10 specified the number of daily cigarettes. A majority (6/10) tended to smoke fewer than 10 cigarettes per day, whereas the others (4/10) reported smoking between 11 and 30 cigarettes per day.

Using the modified American Academy of Neurology (AAN), we classified individuals with asymptomatic impairment, minor cognitive motor disorder, and HIV-associated dementia as cognitively impaired. There were no associations observed between presence of cognitive impairment and either current smoking (Fisher's exact $P = 0.175$) or history of smoking (Fisher's exact $P = 0.293$). There were also no differences in neurocognitive domain test scores between HIV-seropositive and HIV-seronegative women or between those with and those without a history of smoking. However, when the analysis was restricted to HIV-seropositive women, those with a history of smoking had a significantly higher score (i.e., they performed better) on the frontal executive domain ($P = 0.007$) than did those without a history of smoking. There were no differences in cognitive domain performance when the data were stratified by current smoking. When analyzing performance among the individual tests/subtests, we observe that HIV-seropositive women with history of smoking performed better on the Stroop Color Word Test ($P = 0.005$) and the Symbol Digit Modality Test ($P = 0.004$) than those without history of smoking (Table 3). When stratified by current smoking we observed that HIV-seropositive women continued to perform better in the Stroop Color Word Test ($P = .041$) (not shown on Table 3). There were no differences among HIV-seropositive women with either history or current smoker regarding age, education, and annual income.

Discussion

Although women smoke less than men, the prevalence of cigarette smoking in young women is greater than among older women (Williams, 2002). Women who smoke, in contrast to men who smoke, have greater difficulty quitting (Perkins, 2001; MMWR 2006; Perkins *et al*, 2006). In the present study, the HIV-seropositive women began smoking at an earlier age (15.3 years) than the seronegative women. It is known that cigarette smoking is associated with other addictive behaviors (Burns *et al*, 1991; Mamary *et al*, 2002), which could predispose women smokers to risky behaviors such as drug abuse and sexual promiscuity, thus placing them at greater risk of developing HIV infection at an earlier age (CDC, 2006). Younger women with addictive behavior and HIV infection could present with increased risk of cognitive impairment later in life due to the additive effect of comorbid factors (e.g., drug abuse, aging, and HIV infection) (CDC, 2006; Wojna and Nath, 2006). Awareness of the problem and the identification of these women at risk of developing or presenting an addictive behavior could benefit from early intervention (Niaura *et al*, 2000).

Cigarette smoking alters the immune system function. Its effect may depend on the smoker's duration of smoking, gender, and ethnicity (Tollerud *et al*, 1989; Tollerud *et al*, 1991; Sopori, 2002). In our study, HIV-seropositive women with a history of smoking presented with a lower CD4 cell count. These findings are similar to those obtained in the Women's Interagency HIV Study (WIHS) (Feldman *et al*, 2006). Smoking may have an immunosuppressive effect on innate immunity by activating macrophages and adaptive immunity through altered production of antibodies and T-cell responsiveness (Sopori, 2002). Nicotine, as an active compound of cigarette smoking, may also have neuroimmune immunosuppressive effects (Sopori, 2002). These immune changes may make HIV-seropositive women more vulnerable to HIV disease progression. We also found that the HIV-seropositive women in our study presented with higher plasma HIV viral load. Although poor antiretroviral treatment (ART) compliance could be one reason for these findings, nicotine may alter ART metabolism by increasing clearance and decreasing efficacy. The effect of cigarette smoking on ART may vary according to gender. In the Women's Interagency HIV Study (WIHS) longitudinal study, investigators found that HIV-seropositive HAART-compliant women, who were currently smoking, presented poorer viral and immunological response to HAART than did nonsmokers. These findings suggest that in HIV-seropositive women, cigarette smoking may decrease the efficacy of HAART. Contrary to studies involving mostly men in the pre-HAART era, HIV-seropositive women who smoke presented with a higher risk of death and development of AIDS (Feldman *et al*, 2006).

Another factor to consider when studying nicotine's effects in women is that estrogen may synergize with nicotine in neurocognitive function because neurons of the hippocampus have both estrogen and nicotinic receptors (Hosli *et al*, 2000). Estrogen interacts with the $\alpha 7$ nicotinic receptor by attenuating the toxicity induced by amyloid β , thus enhancing nicotine's neuroprotective effect (Svensson and Nordberg, 1999). It is noteworthy that estrogen increases the metabolism of nicotine (Mueck and Seeger, 2005; Benowitz *et al*, 2006).

Although no associations were observed between history of smoking and cognitive status as determined by the mAAN, when the analysis was restricted to HIV-seropositive women, smokers had a significantly higher score (performed better) on the frontal/executive domain (most likely driven by the Stroop Color Word Test performance) and in the Symbol Digit Modality Test, which forms part of our psychomotor speed cognitive domain. Interestingly the performance in the Stroop Color Word performance was maintained in HIV-seropositive women who were currently smoking than did nonsmokers. Comparing our findings with those observed by other investigators evaluating the effect of smoking and nicotine has on cognitive function is difficult because not all investigators use the same neuropsychological battery. However, when comparing our results with those seen in healthy smokers, wherein smoking improved selective attention (as determined by the Stroop Color Word Test) and psychomotor speed (as determined by Reaction Times) our findings are similar (Sacco *et al*, 2004).

Our observational study shows that women with HIV infection presented with an addictive behavior at a younger age, and those of this group who smoked presented with a more

severely altered viral immune profile (lower CD4 cell counts and higher plasma viral loads). However, those HIV-seropositive women who had history of smoking performed better in the frontal/executive cognitive domain and in the Symbol Digit Modality Test as a measure of psychomotor speed. Whereas this finding needs to be confirmed in future studies, it is possible that nicotine may have a beneficial effect on cognition in HIV-seropositive women while using HAART; still, smoking may be detrimental to their immune system. In view of the possible benefits nicotine may offer in improving cognitive performance, it is reasonable to consider studying the dose-response effects of nicotine on cognitive function and viral immune status. Using standardized nicotine dose and administration in clinical trials, we could assess these risk-benefit effects. Along these lines, it will be important to evaluate the use of nicotine in a safer form (e.g., patch, gum, etc.) on the cognitive performance of HIV-infected persons. Furthermore, the presence of nicotinic receptors in peripheral macrophages suggests that nicotine could potentially affect the cholinergic pathway, which might function as an important regulator of inflammation as well as immune responses (Tracey, 2002; Wang *et al*, 2003). Because new antiretroviral agents are available, it is possible that nicotine could serve as an adjuvant treatment in HIV-associated cognitive impairment. Although our study is limited by the sample size, the possibility of cigarette smoking effects on both the immune system and in cognitive function is worth studying further. Controlled clinical trials (e.g., nicotine patches) to evaluate independently the effects of nicotine on the viral immune profile in parallel with its effects on cognitive function in HIV-infected patients could clarify these effects in women with HIV infection.

Methods

Participants and study design

This study was conducted as part of the NeuroAIDS Specialized Neuroscience Research Program (SNRP) at the University of Puerto Rico Medical Sciences Campus. We evaluated 56 women, 20 HIV-seronegative and 36 HIV-seropositive women from the Hispanic-Latino Longitudinal Cohort of HIV-seropositive women, who fulfilled the inclusion criteria of (i) being 18 to 50 years old; (ii) having completed at least the 9th grade of education; and (iii) having a nadir CD4 cell count ≥ 500 cells/mm³ during the past year. Excluded were women with a history of neurodegenerative diseases or prior central nervous system (CNS) infections (e.g., toxoplasmosis), psychiatric conditions, active infections, or head trauma.

Evaluation of participants

The evaluation of participants has been described previously (Wojna *et al*, 2006). After giving their consent to take part in this institutional review board (IRB)-approved research project, individual participants were required to provide demographic and medical history information along with specimens for laboratory analysis. The information included age at enrollment, most likely mode of HIV-1 transmission, nadir and current CD4 cell counts, and menstrual history. Plasma and CSF viral load was determined via Ultrasensitive RNA Roche Amplicor at an Adult Clinical Trial Group (ACTG)-Certified Laboratory. A macroneurological evaluation, performed by the same neurologist (V.W.), consisted of a mental status examination, testing of sensory functions (including response slowing, speed of thought, and language), testing of behavior and mood, as well as standard neurological

evaluations of cranial nerves, cerebellar, motor, reflexes, and sensory evaluations. The evaluating neurologist was blinded to the smoking status. The psychosocial domain of the Menopause-Specific Quality of Life (MENQOL) questionnaire was used (Hilditch *et al*, 1996). The HIV-seronegative group underwent the same evaluations except for the viral and immune profile determinations.

Determination of nicotine use and dependence

The cohort completed a self-reported questionnaire intended to collect information about smoking history, including age of smoking onset, duration of smoking, and smoking interruption. Participants afterwards answered the Spanish translation of the Fagerström Test for Nicotine Dependence (FTND) (Becona and Vazquez, 1998).

Neurocognitive testing

The neuropsychological evaluation included the Wechsler Adult Intelligence Test—Vocabulary subtest and the Woodcock-Muñoz—Reading subtest modalities W31. The second test is a Spanish substitution for the Wide Range Achievement Test previously validated for the Puerto Rican population (Davis and Rodriguez, 1979; Demsky *et al*, 1998). These tests were used to estimate the participants' premorbid cognitive ability status. The neurocognitive testing evaluation consisted of verbal memory (trial 5, delay recall, and recognition of the Rey Auditory Verbal Learning Test), frontal executive function (Stroop Color Word Test—word/color subtest and Trail Making B), psychomotor speed (Symbol Digit Modalities Test and Visual and Auditory Reaction Time nondominant hand), and motor speed (Trail Making A and Grooved Pegboard dominant and nondominant hand). All tests were conducted in Spanish on all patients. We calculated z-scores of the neuropsychological tests in Puerto Rican women, using a reference group of 34 HIV-seronegative women. This reference group did not differ from the HIV-seropositive women group with regard to age, education, and annual income. There were no differences in ethnicity and gender because all participants were Hispanic women. No statistical difference was observed in the premorbid cognitive ability between HIV-seropositive and HIV-seronegative women. These women did not participate in the smoking questionnaire.

Cognitive impairment was determined using the American Academy of Neurology HIV dementia criteria (AAN criteria) (American Academy of Neurology AIDS Task Force, 1991, 1996) modified to include an asymptomatic cognitively impaired group (m-AAN). This asymptomatic cognitively impaired group was defined as patients with abnormal neuropsychological tests (1 SD in two or more tests, or 2 SD in one or more tests, below the normal control group) but who failed to present self-reported functional/ emotional disturbances in quality of life questionnaires or to present neurological deficits (Wojna *et al*, 2006).

Statistical analyses

All statistical analyses were performed with SAS version 8.02 (SAS Institute, Cary, NC) and Intercooled Stata version 8 (StataCorp, College Station, TX). Two-sided hypothesis testing with a type I error threshold for significance of .05 was used to address the primary goal of

the project: examine the associations of smoking history and dependence with viral immune profile and cognitive function in a cohort of HIV-seropositive women.

Following stratification of the cohort by HIV serostatus and history of smoking, group differences in neuropsychological raw scores were assessed by using a two-way analysis of variance (ANOVA). The two factors in this model were HIV serostatus and history of smoking. Among the HIV-seropositive women, differences in demographic characteristics and virologic and immune markers were assessed as a function of current smoking and history of smoking. Continuous variables were assessed using Student's *t* test, and categorical variables were assessed using Fisher's exact test. To test the influence that smoking may have on cognition, we examined differences in cognitive domain and neuropsychological tests/subtests scores using either current smoking or history of smoking as an independent variable. The null hypothesis of no difference was tested using a one-way ANOVA. To adjust for multiple comparisons across the five cognitive domains, we used a Bonferroni-adjusted *P* value of .01 for statistical significance.

Acknowledgments

This work was supported by S11NS046278, U54NS43011, and P20RR11126. P20RR11126 is a grant from the National Center for Research Resources (NCRR) a component of the National Institutes of Health (NIH).

References

- American Academy of Neurology AIDS Task Force. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. *Neurology*. 1991; 41:778–785. [PubMed: 2046917]
- American Academy of Neurology AIDS Task Force. Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. *Neurology*. 1996; 47:1247–1253. [PubMed: 8909438]
- Becona E, Vazquez FL. The Fagerstrom Test for Nicotine Dependence in a Spanish sample. *Psychol Rep*. 1998; 83:1455–1458. [PubMed: 10079737]
- Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P 3rd. Female sex and oral contraceptive use accelerate nicotine metabolism. *Clin Pharmacol Ther*. 2006; 79:480–488. [PubMed: 16678549]
- Burns DN, Kramer A, Yellin F, Fuchs D, Wachter H, DiGioia RA, Sanchez WC, Grossman RJ, Gordin FM, Biggar RJ, Goedert JJ. Cigarette smoking: a modifier of human immunodeficiency virus type 1 infection? *J Acquir Immune Defic Syndr*. 1991; 4:76–83. [PubMed: 1670588]
- CDC. HIV/AIDS among Youth. 2006. <http://www.cdc.gov/hiv/resources/factsheets/youth.htm>
- Conley LJ, Bush TJ, Buchbinder SP, Penley KA, Judson FN, Holmberg SD. The association between cigarette smoking and selected HIV-related medical conditions. *AIDS*. 1996; 10:1121–1126. [PubMed: 8874629]
- Crothers K, Griffith TA, McGinnis KA, Rodriguez-Barradas MC, Leaf DA, Weissman S, Gibert CL, Butt AA, Justice AC. The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans. *J Gen Intern Med*. 2005; 20:1142–1145. [PubMed: 16423106]
- Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. *Annu Rev Pharmacol Toxicol*. 2007; 47:699–729. [PubMed: 17009926]
- Davis TM, Rodriguez VL. Comparison of scores on the WAIS and its Puerto Rican counterpart, Escala de Inteligencia Wechsler para Adultos, in an institutionalized Latin American psychiatric population. *J Consult Clin Psychol*. 1979; 47:181–182. [PubMed: 429653]

- de Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM. Schizophrenia and smoking: an epidemiological survey in a state hospital. *Am J Psychiatry*. 1995; 152:453–455. [PubMed: 7864277]
- De Simone R, Ajmone-Cat MA, Carnevale D, Minghetti L. Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. *J Neuroinflamm*. 2005; 2:4.
- Demsky YI, Gass CS, Golden CJ. Interpretation of VIQ-PIQ and intersubtest differences on the Spanish version of the WAIS. Assessment. 1998; 5:25–30. [PubMed: 9458339]
- Feldman JG, Minkoff H, Schneider MF, Gange SJ, Cohen M, Watts DH, Gandhi M, Mocharnuk RS, Anastos K. Association of cigarette smoking with hiv prognosis among women in the HAART era: a report from the Women's Interagency HIV Study. *Am J Public Health*. 2006; 96:1060–1065. [PubMed: 16670229]
- Furber AS, Maheswaran R, Newell JN, Carroll C. Is smoking tobacco an independent risk factor for HIV infection and progression to AIDS? A systemic review. *Sex Transm Infect*. 2007; 83:41–46. [PubMed: 16923740]
- Galanis DJ, Petrovitch H, Launer LJ, Harris TB, Foley DJ, White LR. Smoking history in middle age and subsequent cognitive performance in elderly Japanese-American men. The Honolulu-Asia Aging Study. *Am J Epidemiol*. 1997; 145:507–515. [PubMed: 9063340]
- Giunta B, Ehrhart J, Townsend K, Sun N, Vendrame M, Shytle D, Tan J, Fernandez F. Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV-1 gp120. *Brain Res Bull*. 2004; 64:165–170. [PubMed: 15342104]
- Gonzalez-Lira B, Rueda-Orozco PE, Galicia O, Montes-Rodriguez CJ, Guzman K, Guevara-Martinez M, Elder JH, Prospero-Garcia O. Nicotine prevents HIVgp120-caused electrophysiological and motor disturbances in rats. *Neurosci Lett*. 2006; 394:136–139. [PubMed: 16269213]
- Gritz ER, Vidrine DJ, Lazev AB, Amick BC 3rd, Arduino RC. Smoking behavior in a low-income multiethnic HIV/AIDS population. *Nicotine Tob Res*. 2004; 6:71–77. [PubMed: 14982690]
- Hilditch JR, Lewis J, Peter A, van Maris B, Ross A, Franssen E, Guyatt GH, Norton PG, Dunn E. A menopause-specific quality of life questionnaire: development and psychometric properties. *Maturitas*. 1996; 24:161–175. [PubMed: 8844630]
- Hill RD, Nilsson LG, Nyberg L, Backman L. Cigarette smoking and cognitive performance in healthy Swedish adults. *Age Ageing*. 2003; 32:548–550. [PubMed: 12958006]
- Holt PG. Immune and inflammatory function in cigarette smokers. *Thorax*. 1987; 42:241–249. [PubMed: 3303428]
- Hosli E, Ruhl W, Hosli L. Histochemical and electrophysiological evidence for estrogen receptors on cultured astrocytes: colocalization with cholinergic receptors. *Int J Dev Neurosci*. 2000; 18:101–111. [PubMed: 10708911]
- Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. *Am J Psychiatry*. 1986; 143:993–997. [PubMed: 3487983]
- Mamary EM, Bahrs D, Martinez S. Cigarette smoking and the desire to quit among individuals living with HIV. *AIDS Patient Care STDS*. 2002; 16:39–42. [PubMed: 11839217]
- Masterson E, O'Shea B. Smoking and malignancy in schizophrenia. *Br J Psychiatry*. 1984; 145:429–432. [PubMed: 6487916]
- MMWR. Use of cessation methods among smokers aged 16–24 years—United States, 2003. *MMWR Mort Morb Wkly Rep*. 2006; 55:1351–1354.
- Mueck AO, Seeger H. Smoking, estradiol metabolism and hormone replacement therapy. *Curr Med Chem Cardiovasc Hematol Agents*. 2005; 3:45–54. [PubMed: 15638743]
- Niaura R, Shadel WG, Morrow K, Tashima K, Flanigan T, Abrams DB. Human immunodeficiency virus infection, AIDS, and smoking cessation: the time is now. *Clin Infect Dis*. 2000; 31:808–812. [PubMed: 11017836]
- O'Farrell TJ, Connors GJ, Upper D. Addictive behaviors among hospitalized psychiatric patients. *Addict Behav*. 1983; 8:329–333. [PubMed: 6610282]
- Olinicy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R. Proof-of-concept trial

- of an alpha7 nicotinic agonist in schizophrenia. *Arch Gen Psychiatry*. 2006; 63:630–638. [PubMed: 16754836]
- Ott A, Andersen K, Dewey ME, Letenneur L, Brayne C, Copeland JR, Dartigues JF, Kragh-Sorensen P, Lobo A, Martinez-Lage JM, Stijnen T, Hofman A, Launer LJ. Effect of smoking on global cognitive function in nondemented elderly. *Neurology*. 2004; 62:920–924. [PubMed: 15037693]
- Page-Shafer K, Delorenze GN, Satariano WA, Winkelstein W Jr. Comorbidity and survival in HIV-infected men in the San Francisco Men's Health Survey. *Ann Epidemiol*. 1996; 6:420–430. [PubMed: 8915473]
- Perkins KA. Smoking cessation in women. Special considerations. *CNS Drugs*. 2001; 15:391–411. [PubMed: 11475944]
- Perkins KA, Doyle T, Ciccocioppo M, Conklin C, Sayette M, Caggiula A. Sex differences in the influence of nicotine dose instructions on the reinforcing and self-reported rewarding effects of smoking. *Psychopharmacology (Berl)*. 2006; 184:600–607. [PubMed: 16075290]
- Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. *AIDS*. 2001; 15:1115–1123. [PubMed: 11416713]
- Razani J, Boone K, Lesser I, Weiss D. Effects of cigarette smoking history on cognitive functioning in healthy older adults. *Am J Geriatr Psychiatry*. 2004; 12:404–411. [PubMed: 15249278]
- Richards M, Jarvis MJ, Thompson N, Wadsworth ME. Cigarette smoking and cognitive decline in midlife: evidence from a prospective birth cohort study. *Am J Public Health*. 2003; 93:994–998. [PubMed: 12773367]
- Royce RA, Winkelstein W Jr. HIV infection, cigarette smoking and CD4+ T-lymphocyte counts: preliminary results from the San Francisco Men's Health Study. *AIDS*. 1990; 4:327–333. [PubMed: 1972021]
- Sacco KA, Bannon KL, George TP. Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. *J Psychopharmacol*. 2004; 18:457–474. [PubMed: 15582913]
- Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC, Krishnan-Sarin S, Jatlow PI, Wexler BE, George TP. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. *Arch Gen Psychiatry*. 2005; 62:649–659. [PubMed: 15939842]
- Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J, Ehrhart J, Silver AA, Sanberg PR, Tan J. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. *J Neurochem*. 2004; 89:337–343. [PubMed: 15056277]
- Sopori M. Effects of cigarette smoke on the immune system. *Nat Rev Immunol*. 2002; 2:372–377. [PubMed: 12033743]
- Svensson AL, Nordberg A. Beta-estradiol attenuate amyloid beta-peptide toxicity via nicotinic receptors. *Neuroreport*. 1999; 10:3485–3489. [PubMed: 10619630]
- Tollerud DJ, Brown LM, Blattner WA, Mann DL, Pankiw-Trost L, Hoover RN. T cell subsets in healthy black smokers and nonsmokers. Evidence for ethnic group as an important response modifier. *Am Rev Respir Dis*. 1991; 144:612–616. [PubMed: 1892301]
- Tollerud DJ, Clark JW, Brown LM, Neuland CY, Mann DL, Pankiw-Trost LK, Blattner WA, Hoover RN. The effects of cigarette smoking on T cell subsets. A population-based survey of healthy caucasians. *Am Rev Respir Dis*. 1989; 139:1446–1451. [PubMed: 2786361]
- Tracey KJ. The inflammatory reflex. *Nature*. 2002; 420:853–859. [PubMed: 12490958]
- Turner J, Page-Shafer K, Chin DP, Osmond D, Mossar M, Markstein L, Huitsing J, Barnes S, Clemente V, Chesney M. Adverse impact of cigarette smoking on dimensions of health-related quality of life in persons with HIV infection. *AIDS Patient Care STDS*. 2001; 15:615–624. [PubMed: 11788076]
- Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. *Nature*. 2003; 421:384–388. [PubMed: 12508119]
- Williams J. Women and smoking: sensory factors, attitudes about weight, phase of menstrual cycle all key to quitting. 2002 NIDA notes.

- Wojna V, Nath A. Challenges to the diagnosis and management of HIV dementia. *AIDS Read*. 2006; 16:615–616. 621–624, 626, 629–632. [PubMed: 17152649]
- Wojna V, Skolasky R, Hechavarria R, Mayo R, Selnes O, McArthur JC, Melendez L, Maldonado E, Zorrilla C, Garcia H, Kraiselburd E, Nath A. Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. *J Neuro Virol*. 2006; 12:1–9.
- Ziedonis DM, Kosten TR, Glazer WM, Frances RJ. Nicotine dependence and schizophrenia. *Hosp Community Psychiatry*. 1994; 45:204–206. [PubMed: 7910577]

Table 1

Demographic characteristics stratified by HIV serostatus

	HIV-1 seropositive (n = 36)	HIV-1 seronegative (n = 20)	P value^a
Age, years ^b	39.8 (6.3)	35.9 (6.2)	.030
Education, years ^b	12.5 (1.7)	12.7 (1.9)	.741
Age started smoking ^b	15.3 (2.3)	18.1 (2.0)	.007
History of smoking ^c	24 (67%)	7 (35%)	.028
Current smoking ^c	15 (42%)	4 (20%)	.143

^aSignificant *P* value <0.05;^bmean (SD);^cnumber (percentage).

Table 2

Virologic and immune markers stratified by current smoking and history of smoking

	Current smoking ^a		History of smoking		<i>P</i> value
	Yes	No	Yes	No	
CD4 cell count, cells/mm ³	275.1 (164.5)	368.8 (221.0)	277.7 (192.0)	433.8 (188.3)	.027
HIV viral load, log ₁₀ copies/ml					
Plasma	3.4 (1.4)	2.5 (1.1)	3.1 (1.4)	2.5 (1.2)	.223
CSF	2.5 (1.1)	2.2 (0.8)	2.3 (0.9)	2.4 (0.9)	.884

^a Mean (SD);

^b significant *P* value <0.05.

Table 3

Neurocognitive domain and neuropsychological tests/subtests scores, stratified by history of smoking

	HIV-seropositive		p-value ^a
	No	Yes	
History of smoking			
I. NPZ ^b	-0.35 (0.60)	0.05 (0.65)	0.085
II. Neuropsychological tests/subtests			
1. Frontal Executive	-1.16 (0.95)	-0.20 (0.93)	0.007
a. Stroop Color Word Test	-1.845 (1.096)	-0.705 (1.077)	0.005
b. Trail Making B	-0.466 (1.431)	0.295 (1.122)	0.089
2. Psychomotor Speed	-0.32 (0.62)	0.08 (0.74)	0.122
a. Symbol Digit Modality Test	-1.019 (0.679)	-0.093 (0.901)	0.004
b. Visual Reaction Time non dominant hand	-0.090 (1.207)	0.124 (1.051)	0.511
c. Auditory Reaction Time non dominant hand	0.162 (0.459)	0.205 (0.682)	0.781
3. Verbal Memory (RAVLT ^c)	-0.08 (0.77)	0.33 (0.61)	0.280
a. Trial 5	-0.497 (0.920)	-0.004 (0.714)	0.687
b. Memory Recall	0.263 (1.006)	0.420 (0.894)	0.608
c. Delayed Recognition	0.466 (0.737)	0.587 (0.584)	0.525
4. Motor Speed	-0.27 (0.83)	-0.10 (1.12)	0.637
a. Trail Making A	-0.383 (1.746)	0.177 (1.438)	0.400
b. Grooved Pegboard dominant hand	-0.077 (0.673)	-0.164 (0.882)	0.988
c. Grooved Pegboard non dominant hand	-0.352 (1.089)	-0.303 (1.613)	0.637
Current smoking			
HIV-seropositive			
	No	Yes	
I. NPZ	-0.15 (0.57)	0.01 (0.76)	0.454
II. Neuropsychological tests/subtests			
1. Frontal Executive	-0.72 (1.03)	-0.24 (0.99)	0.173
2. Psychomotor Speed	-0.06 (0.62)	-0.04 (0.87)	0.912

	HIV-seropositive		p-value ^a
	No	Yes	
3. Verbal Memory	0.23 (0.64)	0.28 (0.72)	0.842
4. Motor Speed	-0.25 (0.85)	-0.02 (1.25)	0.521

^aComparisons made across history of smoking among HIV-1 seropositive using Student's t-test. Significant p value <0.05.

^bNPZ= neuropsychological tests z-score.

^cRey Auditory Verbal Learning Test.